Novartis patents expiration
1. Afinitor patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5665772 | NOVARTIS | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
Sep, 2019
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6004973 | NOVARTIS | Pharmaceutical compositions comprising rafamycin coprecipitates |
Jul, 2016
(7 years ago) | |
|
US6004973 (Pediatric) | NOVARTIS | Pharmaceutical compositions comprising rafamycin coprecipitates |
Jan, 2017
(7 years ago) | |
| US7741338 | NOVARTIS | Macrolides |
Dec, 2019
(4 years ago) | |
| US7297703 | NOVARTIS | Macrolides |
Dec, 2019
(4 years ago) | |
|
US5665772 (Pediatric) | NOVARTIS | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
Mar, 2020
(4 years ago) | |
|
US7297703 (Pediatric) | NOVARTIS | Macrolides |
Jun, 2020
(3 years ago) | |
| US8778962 | NOVARTIS | Treatment of solid tumors with rapamycin derivatives |
Feb, 2022
(2 years ago) | |
| US8436010 | NOVARTIS | Treatment of solid tumors with rapamycin derivatives |
Feb, 2022
(2 years ago) | |
|
US8778962 (Pediatric) | NOVARTIS | Treatment of solid tumors with rapamycin derivatives |
Aug, 2022
(1 year, 8 months ago) | |
|
US8436010 (Pediatric) | NOVARTIS | Treatment of solid tumors with rapamycin derivatives |
Aug, 2022
(1 year, 8 months ago) | |
| US8410131 | NOVARTIS | Cancer treatment |
Nov, 2025
(1 year, 6 months from now) | |
|
US8410131 (Pediatric) | NOVARTIS | Cancer treatment |
May, 2026
(2 years from now) | |
| US9006224 | NOVARTIS | Neuroendocrine tumor treatment |
Jul, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-724) | Feb 26, 2019 |
| Orphan Drug Exclusivity(ODE-108) | Feb 26, 2023 |
| Orphan Drug Exclusivity(ODE-24) | Apr 26, 2019 |
| Orphan Drug Exclusivity(ODE-11) | May 05, 2018 |
| New Chemical Entity Exclusivity(NCE) | Mar 30, 2014 |
| New Indication(I-630) | Oct 29, 2013 |
| New Indication(I-655) | Jul 20, 2015 |
| New Indication(I-650) | Apr 26, 2015 |
| Orphan Drug Exclusivity(ODE) | Apr 26, 2019 |
| Pediatric Exclusivity(PED) | Oct 26, 2015 |
| New Indication(I-638) | May 05, 2014 |
Drugs and Companies using EVEROLIMUS ingredient
NCE-1 date: 26 October, 2014
Market Authorisation Date: 09 July, 2010
Treatment: Treatment of patients with tuberous sclerosis complex (tsc) who have subependymal giant cell astrocytoma (sega) that requires therapeutic intervention but cannot be curatively resected.; Treatment of ...
Dosage: TABLET;ORAL
AFINITOR family patents
2. Alomide patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5457126 | NOVARTIS | Use of lodoxamide to treat ophthalmic allergic conditions |
Oct, 2012
(11 years ago) | |
Drugs and Companies using LODOXAMIDE TROMETHAMINE ingredient
Market Authorisation Date: 23 September, 1993
Treatment: Treatment of ocular allergic response in human eyes
Dosage: SOLUTION/DROPS;OPHTHALMIC
ALOMIDE family patents
3. Amturnide patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5559111 | NOVARTIS | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides |
Jul, 2018
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8618174 | NOVARTIS | Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
Nov, 2021
(2 years ago) | |
| US8183295 | NOVARTIS | Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic |
May, 2023
(11 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 05, 2012 |
| New Combination(NC) | Dec 21, 2013 |
NCE-1 date: 06 March, 2011
Market Authorisation Date: 21 December, 2010
Treatment: Treatment of hypertension
Dosage: TABLET;ORAL
AMTURNIDE family patents
4. Arcapta Neohaler patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8658673 | NOVARTIS | BETA2-adrenoreceptor agonists |
Jun, 2020
(3 years ago) | |
| US8796307 | NOVARTIS | Beta2-adrenoreceptor agonists |
Jun, 2020
(3 years ago) | |
| US6878721 | NOVARTIS | Beta2-adrenoceptor agonists |
Feb, 2025
(9 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8067437 | NOVARTIS | Beta-2-adrenoreceptor agonists |
Jun, 2020
(3 years ago) | |
| US8479730 | NOVARTIS | Inhaler device |
Oct, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 01, 2016 |
Drugs and Companies using INDACATEROL MALEATE ingredient
NCE-1 date: 02 July, 2015
Market Authorisation Date: 01 July, 2011
Treatment: The long term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema
Dosage: POWDER;INHALATION
ARCAPTA NEOHALER family patents
5. Coartem patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5677331 | NOVARTIS | Antimalarial compositions |
Oct, 2014
(9 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 07, 2014 |
| Orphan Drug Exclusivity(ODE) | Apr 07, 2016 |
Drugs and Companies using ARTEMETHER; LUMEFANTRINE ingredient
NCE-1 date: 07 April, 2013
Market Authorisation Date: 07 April, 2009
Treatment: Treatment of acute, uncomplicated malaria infection due to plasmodium falciparum in patients of 5kg bodyweight and above
Dosage: TABLET;ORAL
COARTEM family patents
6. Diovan patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5399578 (Pediatric) | NOVARTIS | Acyl compounds |
Sep, 2012
(11 years ago) | |
| US5972990 | NOVARTIS | Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims |
Oct, 2016
(7 years ago) | |
|
US5972990 (Pediatric) | NOVARTIS | Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims |
Apr, 2017
(7 years ago) | |
| US6294197 | NOVARTIS | Solid oral dosage forms of valsartan |
Jun, 2017
(6 years ago) | |
|
US6294197 (Pediatric) | NOVARTIS | Solid oral dosage forms of valsartan |
Dec, 2017
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Apr 19, 2024 |
Drugs and Companies using VALSARTAN ingredient
Market Authorisation Date: 14 August, 2002
Treatment: Use of valsartan to reduce cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction; Treatment of hypertensi...
Dosage: TABLET;ORAL
DIOVAN family patents
7. Diovan Hct patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5399578 (Pediatric) | NOVARTIS | Acyl compounds |
Sep, 2012
(11 years ago) | |
| US6294197 | NOVARTIS | Solid oral dosage forms of valsartan |
Jun, 2017
(6 years ago) | |
|
US6294197 (Pediatric) | NOVARTIS | Solid oral dosage forms of valsartan |
Dec, 2017
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-567) | Jul 31, 2011 |
Drugs and Companies using HYDROCHLOROTHIAZIDE; VALSARTAN ingredient
Market Authorisation Date: 06 March, 1998
Treatment: Treatment of hypertension
Dosage: TABLET;ORAL
DIOVAN HCT family patents
8. Emadine patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5441958 | NOVARTIS | Ophthalmic compositions comprising emedastine and methods for their use |
Dec, 2013
(10 years ago) | |
Drugs and Companies using EMEDASTINE DIFUMARATE ingredient
Market Authorisation Date: 29 December, 1997
Treatment: Treatment of allergic conjunctivitis
Dosage: SOLUTION/DROPS;OPHTHALMIC
EMADINE family patents
9. Exelon patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US4948807 | NOVARTIS | Phenyl carbamates |
Aug, 2012
(11 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5602176 | NOVARTIS | Phenyl carbamate |
Feb, 2014
(10 years ago) | |
Drugs and Companies using RIVASTIGMINE TARTRATE ingredient
Market Authorisation Date: 21 April, 2000
Treatment: Treatment of alzheimer's dementia
Dosage: SOLUTION;ORAL; CAPSULE;ORAL
EXELON family patents
10. Exforge patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5399578 (Pediatric) | NOVARTIS | Acyl compounds |
Sep, 2012
(11 years ago) | |
| US6294197 | NOVARTIS | Solid oral dosage forms of valsartan |
Jun, 2017
(6 years ago) | |
|
US6294197 (Pediatric) | NOVARTIS | Solid oral dosage forms of valsartan |
Dec, 2017
(6 years ago) | |
| US6395728 | NOVARTIS | Method of treatment and pharmaceutical composition |
Jul, 2019
(4 years ago) | |
Drugs and Companies using AMLODIPINE BESYLATE; VALSARTAN ingredient
Market Authorisation Date: 20 June, 2007
Treatment: Treatment of hypertension
Dosage: TABLET;ORAL
EXFORGE family patents
11. Exforge Hct patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5399578 (Pediatric) | NOVARTIS | Acyl compounds |
Sep, 2012
(11 years ago) | |
| US6294197 | NOVARTIS | Solid oral dosage forms of valsartan |
Jun, 2017
(6 years ago) | |
|
US6294197 (Pediatric) | NOVARTIS | Solid oral dosage forms of valsartan |
Dec, 2017
(6 years ago) | |
| US8475839 | NOVARTIS | Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same |
May, 2023
(11 months ago) | |
| US8101599 | NOVARTIS | Pharmaceutical composition containing anti-hypertensive agents |
May, 2023
(11 months ago) | |
|
US8475839 (Pediatric) | NOVARTIS | Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same |
Nov, 2023
(5 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Apr 30, 2012 |
Drugs and Companies using AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN ingredient
Market Authorisation Date: 30 April, 2009
Treatment: Treatment of hypertension
Dosage: TABLET;ORAL
EXFORGE HCT family patents
12. Exjade patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6596750 | NOVARTIS | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
Jun, 2017
(6 years ago) | |
| US6465504 | NOVARTIS | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
Apr, 2019
(5 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-239) | Dec 12, 2021 |
| Orphan Drug Exclusivity(ODE-39) | Jan 23, 2020 |
| M(M-241) | Jul 24, 2022 |
| M(M-263) | Jul 23, 2023 |
| Orphan Drug Exclusivity(ODE) | Nov 02, 2012 |
| New Indication(I-665) | Jan 23, 2016 |
Drugs and Companies using DEFERASIROX ingredient
Market Authorisation Date: 02 November, 2005
Treatment: Method of treating chronic iron overload
Dosage: TABLET, FOR SUSPENSION;ORAL
EXJADE family patents
13. Fabhalta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9682968 | NOVARTIS | Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof |
Jul, 2034
(10 years from now) | |
| US11603363 | NOVARTIS | Crystalline form of LNP023 |
May, 2041
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2028 |
| Orphan Drug Exclusivity(ODE-456) | Dec 05, 2030 |
Drugs and Companies using IPTACOPAN HYDROCHLORIDE ingredient
NCE-1 date: 06 December, 2027
Market Authorisation Date: 05 December, 2023
Treatment: NA
Dosage: CAPSULE;ORAL
FABHALTA family patents
14. Famvir patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6124304 | NOVARTIS | Penciclovir for the treatment of zoster associated pain |
Oct, 2014
(9 years ago) | |
| US5866581 | NOVARTIS | Penciclovir for the treatment of post therapeutic neuralgia |
Oct, 2014
(9 years ago) | |
|
US6124304 (Pediatric) | NOVARTIS | Penciclovir for the treatment of zoster associated pain |
Apr, 2015
(9 years ago) | |
|
US5866581 (Pediatric) | NOVARTIS | Penciclovir for the treatment of post therapeutic neuralgia |
Apr, 2015
(9 years ago) | |
| US5840763 | NOVARTIS | Treatment of a latent infection of herpes viruses |
Sep, 2015
(8 years ago) | |
| US5916893 | NOVARTIS | Treatment of a latent infection of herpes virus |
Sep, 2015
(8 years ago) | |
|
US5916893 (Pediatric) | NOVARTIS | Treatment of a latent infection of herpes virus |
Mar, 2016
(8 years ago) | |
|
US5840763 (Pediatric) | NOVARTIS | Treatment of a latent infection of herpes viruses |
Mar, 2016
(8 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-54) | Dec 24, 2012 |
| M(M-98) | Jan 31, 2014 |
| M(M-112) | Feb 09, 2015 |
| Pediatric Exclusivity(PED) | Jun 24, 2013 |
Drugs and Companies using FAMCICLOVIR ingredient
Market Authorisation Date: 11 December, 1995
Treatment: Method of treating varicella zoster (shingles) infections
Dosage: TABLET;ORAL
FAMVIR family patents
15. Foradil patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6488027 | NOVARTIS | Powder inhaler |
Mar, 2019
(5 years ago) | |
| US6887459 | NOVARTIS | Aerosol composition comprising formoterol |
Nov, 2020
(3 years ago) | |
Drugs and Companies using FORMOTEROL FUMARATE ingredient
Market Authorisation Date: 16 February, 2001
Treatment: Treatment of chronic obstructive pulmonary disease
Dosage: POWDER;INHALATION
FORADIL family patents
16. Gilenya patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5604229 | NOVARTIS | 2-amino-1,3-propanediol compound and immunosuppressant |
Feb, 2019
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6004565 | NOVARTIS | Compositions and methods of using compositions with accelerated lymphocyte homing immunosuppressive properties |
Sep, 2017
(6 years ago) | |
|
US5604229 (Pediatric) | NOVARTIS | 2-amino-1,3-propanediol compound and immunosuppressant |
Aug, 2019
(4 years ago) | |
| US8324283 | NOVARTIS | Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol |
Mar, 2026
(1 year, 11 months from now) | |
|
US8324283 (Pediatric) | NOVARTIS | Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol |
Sep, 2026
(2 years from now) | |
| US9187405 | NOVARTIS | S1P receptor modulators for treating relasping-remitting multiple sclerosis |
Jun, 2027
(3 years from now) | |
|
US9187405 (Pediatric) | NOVARTIS | S1P receptor modulators for treating relasping-remitting multiple sclerosis |
Dec, 2027
(3 years from now) | |
| US10543179 | NOVARTIS | Dosage regimen of an S1P receptor modulator |
Dec, 2027
(3 years from now) | |
| US9592208 | NOVARTIS | Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol |
Mar, 2032
(7 years from now) | |
|
US9592208 (Pediatric) | NOVARTIS | Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol |
Sep, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | May 11, 2021 |
| New Patient Population(NPP) | May 11, 2021 |
| Pediatric Exclusivity(PED) | Nov 11, 2021 |
| M(M-106) | Jul 20, 2014 |
| New Chemical Entity Exclusivity(NCE) | Sep 21, 2015 |
Drugs and Companies using FINGOLIMOD HYDROCHLORIDE ingredient
NCE-1 date: 11 November, 2020
Market Authorisation Date: 11 May, 2018
Treatment: Treatment of autoimmune disease; Treatment of relapsing-remitting sclerosis (ms); Treatment of relapsing remitting multiple sclerosis by determining varicella zoster virus (vzv) status and vaccinating...
Dosage: CAPSULE;ORAL
GILENYA family patents
17. Gleevec patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5521184 | NOVARTIS | Pyrimidine derivatives and processes for the preparation thereof |
Jan, 2015
(9 years ago) | |
| USRE43932 | NOVARTIS | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
Jul, 2018
(5 years ago) | |
| US7544799 | NOVARTIS | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
Jul, 2018
(5 years ago) | |
| US6894051 | NOVARTIS | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
May, 2019
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5521184 | NOVARTIS | Pyrimidine derivatives and processes for the preparation thereof |
Jan, 2015
(9 years ago) | |
|
US5521184 (Pediatric) | NOVARTIS | Pyrimidine derivatives and processes for the preparation thereof |
Jul, 2015
(8 years ago) | |
|
US7544799 (Pediatric) | NOVARTIS | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
Jan, 2019
(5 years ago) | |
|
USRE43932 (Pediatric) | NOVARTIS | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
Jan, 2019
(5 years ago) | |
|
US6894051 (Pediatric) | NOVARTIS | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
Nov, 2019
(4 years ago) | |
| US6958335 | NOVARTIS | Treatment of gastrointestinal stromal tumors |
Dec, 2021
(2 years ago) | |
|
US6958335 (Pediatric) | NOVARTIS | Treatment of gastrointestinal stromal tumors |
Jun, 2022
(1 year, 10 months ago) | |
Drugs and Companies using IMATINIB MESYLATE ingredient
Market Authorisation Date: 10 May, 2001
Treatment: Gleevec is also indicated for the treatment of patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (gist); A method for treating a tumor disease
Dosage: CAPSULE;ORAL; TABLET;ORAL
GLEEVEC family patents
18. Izba patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9144561 | NOVARTIS | Pharmaceutical compositions having desirable bioavailability |
Mar, 2029
(4 years from now) | |
| US8754123 | NOVARTIS | Pharmaceutical compositions having desirable bioavailability |
May, 2029
(5 years from now) | |
| US8178582 | NOVARTIS | Pharmaceutical compositions having desirable bioavailability |
Oct, 2029
(5 years from now) | |
| US8722735 | NOVARTIS | Pharmaceutical compositions having desirable bioavailability |
Oct, 2029
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 15, 2017 |
Drugs and Companies using TRAVOPROST ingredient
Market Authorisation Date: 15 May, 2014
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
IZBA family patents
19. Jadenu Sprinkle patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6465504 | NOVARTIS | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
Apr, 2019
(5 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-241) | Jul 24, 2022 |
| M(M-239) | Dec 12, 2021 |
| M(M-263) | Jul 23, 2023 |
Drugs and Companies using DEFERASIROX ingredient
Market Authorisation Date: 18 May, 2017
Treatment: NA
Dosage: GRANULE;ORAL
JADENU SPRINKLE family patents
20. Kisqali patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8324225 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Jun, 2028
(4 years from now) | |
| US8685980 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
May, 2030
(6 years from now) | |
| US8415355 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Mar, 2031
(6 years from now) | |
| US9193732 | NOVARTIS | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
Nov, 2031
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9416136 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Aug, 2029
(5 years from now) | |
| US8962630 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Dec, 2029
(5 years from now) | |
| US9868739 | NOVARTIS | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
Nov, 2031
(7 years from now) | |
| US10799506 | NOVARTIS | Ribociclib tablet |
Apr, 2036
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 10, 2024 |
| New Chemical Entity Exclusivity(NCE) | Mar 13, 2022 |
| New Indication(I-784) | Jul 18, 2021 |
| New Indication(I-783) | Jul 18, 2021 |
Drugs and Companies using RIBOCICLIB SUCCINATE ingredient
NCE-1 date: 13 March, 2021
Market Authorisation Date: 13 March, 2017
Treatment: In combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-n...
Dosage: TABLET;ORAL
KISQALI family patents
21. Kisqali Femara Co-pack (copackaged) patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8324225 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Jun, 2028
(4 years from now) | |
| US8685980 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
May, 2030
(6 years from now) | |
| US8415355 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Mar, 2031
(6 years from now) | |
| US9193732 | NOVARTIS | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
Nov, 2031
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9416136 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Aug, 2029
(5 years from now) | |
| US8962630 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Dec, 2029
(5 years from now) | |
| US9868739 | NOVARTIS | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
Nov, 2031
(7 years from now) | |
| US10799506 | NOVARTIS | Ribociclib tablet |
Apr, 2036
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 10, 2024 |
| New Chemical Entity Exclusivity(NCE) | Mar 13, 2022 |
Drugs and Companies using LETROZOLE; RIBOCICLIB SUCCINATE ingredient
NCE-1 date: 13 March, 2021
Market Authorisation Date: 04 May, 2017
Treatment: As initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cance...
Dosage: TABLET;ORAL
KISQALI FEMARA CO-PACK (COPACKAGED) family patents
22. Leqvio patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9074213 | NOVARTIS | Compositions and methods for inhibiting expression of a target gene |
Mar, 2022
(2 years ago) | |
| US8546143 | NOVARTIS | Compositions and methods for inhibiting expression of a target gene |
Apr, 2022
(2 years ago) | |
| US8232383 | NOVARTIS | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
Feb, 2023
(1 year, 2 months ago) | |
| US11078485 | NOVARTIS | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Nov, 2023
(5 months ago) | |
| US9708610 | NOVARTIS | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Jan, 2024
(3 months ago) | |
| US10273477 | NOVARTIS | Therapeutic compositions |
Mar, 2024
(a month ago) | |
| US10669544 | NOVARTIS | Therapeutic compositions |
Mar, 2024
(a month ago) | |
| US9708615 | NOVARTIS | Therapeutic compositions |
Mar, 2024
(a month ago) | |
| US11530408 | NOVARTIS | Therapeutic compositions |
May, 2024
(21 days from now) | |
| US8809292 | NOVARTIS | Compositions and methods for inhibiting expression of the PCSK9 gene |
May, 2027
(3 years from now) | |
| US10131907 | NOVARTIS | Glycoconjugates of RNA interference agents |
Aug, 2028
(4 years from now) | |
| US10806791 | NOVARTIS | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(4 years from now) | |
| US8828956 | NOVARTIS | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(4 years from now) | |
| US9370582 | NOVARTIS | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(4 years from now) | |
| US8106022 | NOVARTIS | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2029
(5 years from now) | |
| US10125369 | NOVARTIS | PCSK9 iRNA compositions and methods of use thereof |
Aug, 2034
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10590418 | NOVARTIS | Methods and compositions for RNAi mediated inhibition of gene expression in mammals |
Jul, 2022
(1 year, 9 months ago) | |
| US10266825 | NOVARTIS | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Nov, 2023
(5 months ago) | |
| US8222222 | NOVARTIS | Compositions and methods for inhibiting expression of the PCSK9 gene |
Dec, 2027
(3 years from now) | |
| US10851377 | NOVARTIS | Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder |
Aug, 2036
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 22, 2026 |
Drugs and Companies using INCLISIRAN SODIUM ingredient
NCE-1 date: 22 December, 2025
Market Authorisation Date: 22 December, 2021
Treatment: As an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (hefh) or clinical atherosclerotic cardiovascular disease (ascv...
Dosage: SOLUTION;SUBCUTANEOUS
LEQVIO family patents
23. Locametz patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11369590 | NOVARTIS | PSMA binding ligand-linker conjugates and methods for using |
Aug, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 23, 2025 |
Drugs and Companies using GALLIUM GA-68 GOZETOTIDE ingredient
Market Authorisation Date: 23 March, 2022
Treatment: For use after radiolabeling with gallium-68, for positron emission tomography of prostate-specific membrane antigen (psma)-positive lesions in men with prostate cancer
Dosage: POWDER;INTRAVENOUS
LOCAMETZ family patents
24. Mayzent patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7939519 | NOVARTIS | Immunosuppresant compounds and compositions |
Aug, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8492441 | NOVARTIS | Dosage regimen of an S1P receptor agonist |
Nov, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 26, 2024 |
| M(M-274) | Mar 01, 2025 |
Drugs and Companies using SIPONIMOD ingredient
NCE-1 date: 27 March, 2023
Market Authorisation Date: 26 March, 2019
Treatment: A method of treating multiple sclerosis by administering siponimod using a titration scheme to reach a maintenance dose
Dosage: TABLET;ORAL
MAYZENT family patents
25. Mekinist patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7378423 | NOVARTIS | Pyrimidine compound and medical use thereof |
May, 2027
(3 years from now) | |
| US8703781 | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors |
Oct, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8835443 | NOVARTIS | Pyrimidine compound and medical use thereof |
Jun, 2025
(1 year, 1 month from now) | |
|
US8835443 (Pediatric) | NOVARTIS | Pyrimidine compound and medical use thereof |
Dec, 2025
(1 year, 7 months from now) | |
|
US7378423 (Pediatric) | NOVARTIS | Pyrimidine compound and medical use thereof |
Nov, 2027
(3 years from now) | |
| US8952018 | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors |
Oct, 2030
(6 years from now) | |
|
US8952018 (Pediatric) | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors |
Apr, 2031
(6 years from now) | |
|
US8703781 (Pediatric) | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors |
Apr, 2031
(6 years from now) | |
| US8580304 | NOVARTIS | Pharmaceutical composition |
Jan, 2032
(7 years from now) | |
| US9271941 | NOVARTIS | Pharmaceutical composition |
Jan, 2032
(7 years from now) | |
| US9155706 | NOVARTIS | Pharmaceutical composition |
Jan, 2032
(7 years from now) | |
| US9399021 | NOVARTIS | Pharmaceutical composition |
Jan, 2032
(7 years from now) | |
|
US9155706 (Pediatric) | NOVARTIS | Pharmaceutical composition |
Jul, 2032
(8 years from now) | |
|
US9399021 (Pediatric) | NOVARTIS | Pharmaceutical composition |
Jul, 2032
(8 years from now) | |
|
US8580304 (Pediatric) | NOVARTIS | Pharmaceutical composition |
Jul, 2032
(8 years from now) | |
|
US9271941 (Pediatric) | NOVARTIS | Pharmaceutical composition |
Jul, 2032
(8 years from now) | |
| US10869869 | NOVARTIS | Method of adjuvant cancer treatment |
Aug, 2033
(9 years from now) | |
|
US10869869 (Pediatric) | NOVARTIS | Method of adjuvant cancer treatment |
Mar, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-182) | Apr 30, 2025 |
| Orphan Drug Exclusivity(ODE-183) | May 04, 2025 |
| Orphan Drug Exclusivity(ODE-148) | Jun 22, 2024 |
| New Indication(I-908) | Mar 16, 2026 |
| Orphan Drug Exclusivity(ODE-428) | Mar 16, 2030 |
| New Indication(I-895) | Jun 22, 2025 |
| Pediatric Exclusivity(PED) | Dec 22, 2025 |
| New Indication(I-745) | Jun 22, 2020 |
| Orphan Drug Exclusivity(ODE-48) | May 29, 2020 |
| M(M-170) | Nov 20, 2018 |
| Orphan Drug Exclusivity(ODE-57) | Jan 08, 2021 |
| New Indication(I-678) | Jan 08, 2017 |
| M(M-246) | Oct 06, 2022 |
| New Indication(I-778) | Apr 30, 2021 |
| New Indication(I-781) | May 04, 2021 |
| Orphan Drug Exclusivity(ODE) | May 29, 2020 |
| New Chemical Entity Exclusivity(NCE) | May 29, 2018 |
Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient
NCE-1 date: 22 December, 2024
Market Authorisation Date: 29 May, 2013
Treatment: Mekinist is indicated, in combination with dabrafenib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (atc) with braf v600e mutation and with no satisfacto...
Dosage: TABLET;ORAL; SOLUTION;ORAL
MEKINIST family patents
26. Myfortic patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6025391 | NOVARTIS | Enteric-coated pharmaceutical compositions of mycophenolate |
Apr, 2017
(7 years ago) | |
| US6172107 | NOVARTIS | Entric-coated pharmaceutical compositions |
Apr, 2017
(7 years ago) | |
| US6306900 | NOVARTIS | Enteric coated pharmaceutical compositions |
Feb, 2018
(6 years ago) | |
Drugs and Companies using MYCOPHENOLIC SODIUM ingredient
Market Authorisation Date: 27 February, 2004
Treatment: Prophylaxis of organ rejection in patients receiving allogeneic renal transplants
Dosage: TABLET, DELAYED RELEASE;ORAL
MYFORTIC family patents
27. Neoral patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5985321 | NOVARTIS | Soft gelatin capsule manufacture |
Sep, 2014
(9 years ago) | |
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 14 July, 1995
Treatment: NA
Dosage: SOLUTION;ORAL; CAPSULE;ORAL
NEORAL family patents
28. Patanase patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8399508 | NOVARTIS | Olopatadine formulations for topical nasal administration |
Sep, 2022
(1 year, 7 months ago) | |
| US7977376 | NOVARTIS | Olopatadine formulations for topical nasal administration |
Feb, 2023
(1 year, 2 months ago) | |
|
US8399508 (Pediatric) | NOVARTIS | Olopatadine formulations for topical nasal administration |
Mar, 2023
(1 year, 1 month ago) | |
|
US7977376 (Pediatric) | NOVARTIS | Olopatadine formulations for topical nasal administration |
Aug, 2023
(8 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Jun 01, 2013 |
| New Patient Population(NPP) | Dec 01, 2012 |
Drugs and Companies using OLOPATADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 15 April, 2008
Treatment: Allergic rhinitis
Dosage: SPRAY, METERED;NASAL
PATANASE family patents
29. Piqray patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8476268 | NOVARTIS | Pyrrolidine-1,2-dicarboxamide derivatives |
Sep, 2029
(5 years from now) | |
| US8227462 | NOVARTIS | Pyrrolidine-1,2-dicarboxamide derivatives |
Apr, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 24, 2024 |
| New Indication(I-937) | Jan 18, 2027 |
Drugs and Companies using ALPELISIB ingredient
NCE-1 date: 25 May, 2023
Market Authorisation Date: 24 May, 2019
Treatment: In combination with fulvestrant for treatment of postmenopausal women, and men, with hr-positive, her-2-negative, pik3ca-mutated, advanced or metastatic breast cancer
Dosage: TABLET;ORAL
PIQRAY family patents
30. Pluvicto patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10406240 | NOVARTIS | PSMA binding ligand-linker conjugates and methods for using |
Aug, 2028
(4 years from now) | |
| US11318121 | NOVARTIS | PSMA binding ligand-linker conjugates and methods for using |
Aug, 2028
(4 years from now) | |
| US10398791 | NOVARTIS | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
Oct, 2034
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 23, 2027 |
Drugs and Companies using LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN ingredient
NCE-1 date: 23 March, 2026
Market Authorisation Date: 23 March, 2022
Treatment: For treatment of adult patients with prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with androgen receptor (ar) pathwa...
Dosage: SOLUTION;INTRAVENOUS
PLUVICTO family patents
31. Promacta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6280959 | NOVARTIS | Metal complexes |
Oct, 2018
(5 years ago) | |
| US7473686 | NOVARTIS | Thrombopoietin mimetics |
May, 2021
(2 years ago) | |
| US7452874 | NOVARTIS | Thrombopoietin mimetics |
May, 2021
(2 years ago) | |
| US7160870 | NOVARTIS | Thrombopoietin mimetics |
Nov, 2022
(1 year, 5 months ago) | |
| US7547719 | NOVARTIS | 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) |
Jul, 2025
(1 year, 2 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6280959 (Pediatric) | NOVARTIS | Metal complexes |
Apr, 2019
(4 years ago) | |
| US7790704 | NOVARTIS | Thrombopoietin mimetics |
May, 2021
(2 years ago) | |
| US7332481 | NOVARTIS | Thrombopoietin mimetics |
May, 2021
(2 years ago) | |
|
US7332481 (Pediatric) | NOVARTIS | Thrombopoietin mimetics |
Nov, 2021
(2 years ago) | |
|
US7452874 (Pediatric) | NOVARTIS | Thrombopoietin mimetics |
Nov, 2021
(2 years ago) | |
|
US7790704 (Pediatric) | NOVARTIS | Thrombopoietin mimetics |
Nov, 2021
(2 years ago) | |
|
US7473686 (Pediatric) | NOVARTIS | Thrombopoietin mimetics |
Nov, 2021
(2 years ago) | |
|
US7160870 (Pediatric) | NOVARTIS | Thrombopoietin mimetics |
May, 2023
(11 months ago) | |
| US7795293 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
May, 2023
(11 months ago) | |
|
US7795293 (Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Nov, 2023
(5 months ago) | |
|
US7547719 (Pediatric) | NOVARTIS | 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) |
Jan, 2026
(1 year, 8 months from now) | |
| US8828430 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Aug, 2027
(3 years from now) | |
| US8052995 | NOVARTIS | 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Aug, 2027
(3 years from now) | |
| US8052993 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Aug, 2027
(3 years from now) | |
| US8071129 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Aug, 2027
(3 years from now) | |
| US8062665 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Aug, 2027
(3 years from now) | |
| US8052994 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Aug, 2027
(3 years from now) | |
|
US8052993 (Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Feb, 2028
(3 years from now) | |
|
US8062665 (Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Feb, 2028
(3 years from now) | |
|
US8071129 (Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Feb, 2028
(3 years from now) | |
|
US8052994 (Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Feb, 2028
(3 years from now) | |
|
US8052995 (Pediatric) | NOVARTIS | 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Feb, 2028
(3 years from now) | |
|
US8828430 (Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Feb, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-210) | Nov 16, 2025 |
| New Indication(I-711) | Jun 11, 2018 |
| New Dosing Schedule(D-149) | Jun 11, 2018 |
| Pediatric Exclusivity(PED) | Feb 26, 2022 |
| Orphan Drug Exclusivity(ODE-75) | Aug 26, 2021 |
| New Indication(I-664) | Nov 16, 2015 |
| New Chemical Entity Exclusivity(NCE) | Nov 20, 2013 |
| Orphan Drug Exclusivity(ODE) | Nov 20, 2015 |
Drugs and Companies using ELTROMBOPAG OLAMINE ingredient
NCE-1 date: 26 February, 2021
Market Authorisation Date: 20 October, 2011
Treatment: Treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (itp); Treatment of thrombocytopenia in patients with chronic hepatitis...
Dosage: TABLET;ORAL
PROMACTA family patents
32. Promacta Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6280959 | NOVARTIS | Metal complexes |
Oct, 2018
(5 years ago) | |
| US7452874 | NOVARTIS | Thrombopoietin mimetics |
May, 2021
(2 years ago) | |
| US7473686 | NOVARTIS | Thrombopoietin mimetics |
May, 2021
(2 years ago) | |
| US7160870 | NOVARTIS | Thrombopoietin mimetics |
Nov, 2022
(1 year, 5 months ago) | |
| US7547719 | NOVARTIS | 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) |
Jul, 2025
(1 year, 2 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6280959 (Pediatric) | NOVARTIS | Metal complexes |
Apr, 2019
(4 years ago) | |
| US7790704 | NOVARTIS | Thrombopoietin mimetics |
May, 2021
(2 years ago) | |
| US7332481 | NOVARTIS | Thrombopoietin mimetics |
May, 2021
(2 years ago) | |
|
US7473686 (Pediatric) | NOVARTIS | Thrombopoietin mimetics |
Nov, 2021
(2 years ago) | |
|
US7790704 (Pediatric) | NOVARTIS | Thrombopoietin mimetics |
Nov, 2021
(2 years ago) | |
|
US7332481 (Pediatric) | NOVARTIS | Thrombopoietin mimetics |
Nov, 2021
(2 years ago) | |
|
US7452874 (Pediatric) | NOVARTIS | Thrombopoietin mimetics |
Nov, 2021
(2 years ago) | |
|
US7160870 (Pediatric) | NOVARTIS | Thrombopoietin mimetics |
May, 2023
(11 months ago) | |
| US7795293 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
May, 2023
(11 months ago) | |
|
US7795293 (Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Nov, 2023
(5 months ago) | |
|
US7547719 (Pediatric) | NOVARTIS | 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) |
Jan, 2026
(1 year, 8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| ODE*(ODE*) | Nov 16, 2025 |
| New Dosing Schedule(D-149) | Jun 11, 2018 |
| New Indication(I-711) | Jun 11, 2018 |
| Orphan Drug Exclusivity(ODE) | Aug 26, 2021 |
| Pediatric Exclusivity(PED) | Feb 26, 2022 |
| Orphan Drug Exclusivity(ODE-74) | Aug 26, 2021 |
Drugs and Companies using ELTROMBOPAG OLAMINE ingredient
Market Authorisation Date: 27 September, 2018
Treatment: Treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (itp); Treatment of thrombocytopenia in patients with chronic hepatitis...
Dosage: FOR SUSPENSION;ORAL
PROMACTA KIT family patents
33. Rydapt patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8222244 | NOVARTIS | Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity |
Oct, 2022
(1 year, 5 months ago) | |
| US7973031 | NOVARTIS | Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity |
Oct, 2028
(4 years from now) | |
| US8575146 | NOVARTIS | Pharmaceutical uses of staurosporine derivatives |
Dec, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-140) | Apr 28, 2024 |
| Orphan Drug Exclusivity(ODE-141) | Apr 28, 2024 |
| Orphan Drug Exclusivity(ODE) | Apr 28, 2024 |
| New Chemical Entity Exclusivity(NCE) | Apr 28, 2022 |
Drugs and Companies using MIDOSTAURIN ingredient
NCE-1 date: 28 April, 2021
Market Authorisation Date: 28 April, 2017
Treatment: Treatment of adult patients with newly diagnosed acute myeloid leukemia (aml) who are flt3 mutation-positive, in combination with standard cytarabine and daunorubicin induction and cytarabine consolid...
Dosage: CAPSULE;ORAL
RYDAPT family patents
34. Sandostatin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5753618 | NOVARTIS | Somatostatin analogue composition and use in treating breast cancer |
May, 2015
(8 years ago) | |
|
US5753618 (Pediatric) | NOVARTIS | Somatostatin analogue composition and use in treating breast cancer |
Nov, 2015
(8 years ago) | |
Drugs and Companies using OCTREOTIDE ACETATE ingredient
Market Authorisation Date: 21 October, 1988
Treatment: NA
Dosage: INJECTABLE;INJECTION
SANDOSTATIN family patents
35. Sandostatin Lar patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5538739 | NOVARTIS | Sustained release formulations of water soluble peptides |
Jul, 2013
(10 years ago) | |
|
US5538739 (Pediatric) | NOVARTIS | Sustained release formulations of water soluble peptides |
Jan, 2014
(10 years ago) | |
| US5639480 | NOVARTIS | Sustained release formulations of water soluble peptides |
Jun, 2014
(9 years ago) | |
| US5688530 | NOVARTIS | Sustained release formulations of water soluble peptides |
Nov, 2014
(9 years ago) | |
|
US5639480 (Pediatric) | NOVARTIS | Sustained release formulations of water soluble peptides |
Dec, 2014
(9 years ago) | |
|
US5688530 (Pediatric) | NOVARTIS | Sustained release formulations of water soluble peptides |
May, 2015
(8 years ago) | |
| US5922338 | NOVARTIS | Polyol esters, their preparation and use in depot forms of pharmacologically active agents |
Jul, 2016
(7 years ago) | |
| US5922682 | NOVARTIS | Polyol esters, their preparation and use in depot forms of pharmacologically active agents |
Jul, 2016
(7 years ago) | |
|
US5922682 (Pediatric) | NOVARTIS | Polyol esters, their preparation and use in depot forms of pharmacologically active agents |
Jan, 2017
(7 years ago) | |
|
US5922338 (Pediatric) | NOVARTIS | Polyol esters, their preparation and use in depot forms of pharmacologically active agents |
Jan, 2017
(7 years ago) | |
Drugs and Companies using OCTREOTIDE ACETATE ingredient
Market Authorisation Date: 25 November, 1998
Treatment: Acromegaly
Dosage: INJECTABLE;INJECTION
SANDOSTATIN LAR family patents
36. Scemblix patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8829195 | NOVARTIS | Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 |
May, 2033
(9 years from now) | |
| US11407735 | NOVARTIS | Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide |
May, 2040
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 29, 2026 |
| Orphan Drug Exclusivity(ODE-382) | Oct 29, 2028 |
| Orphan Drug Exclusivity(ODE-381) | Oct 29, 2028 |
Drugs and Companies using ASCIMINIB HYDROCHLORIDE ingredient
NCE-1 date: 29 October, 2025
Market Authorisation Date: 29 October, 2021
Treatment: Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml)
Dosage: TABLET;ORAL
SCEMBLIX family patents
37. Seebri patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6521260 | NOVARTIS | Carrier particles for use in dry powder inhalers |
Jan, 2016
(8 years ago) | |
| US6528678 | NOVARTIS | Phosgene-free process for preparing carbamates |
Apr, 2018
(6 years ago) | |
| US6582678 | NOVARTIS | Carrier particles for use in dry powder inhalers |
Apr, 2018
(6 years ago) | |
| US8029768 | NOVARTIS | Treatment of respiratory diseases |
Apr, 2021
(3 years ago) | |
| US7229607 | NOVARTIS | Treatment of respiratory disease |
Apr, 2021
(3 years ago) | |
| US9962338 | NOVARTIS | Method of making particles for use in a pharmaceutical composition |
Jun, 2021
(2 years ago) | |
| US8303991 | NOVARTIS | Method of making particles for use in a pharmaceutical composition |
Jun, 2021
(2 years ago) | |
| US8048451 | NOVARTIS | Pharmaceutical compositions for inhalation |
Jun, 2021
(2 years ago) | |
| US8580306 | NOVARTIS | Particles for use in a pharmaceutical composition |
Jun, 2021
(2 years ago) | |
| US8435567 | NOVARTIS | Pharmaceutical compositions of hydrophobic surface-modified active substance microparticles for inhalation |
Jun, 2021
(2 years ago) | |
| US9931304 | NOVARTIS | Method of making particles for use in a pharmaceutical composition |
Jun, 2021
(2 years ago) | |
| US8956661 | NOVARTIS | Method of making composite particles for use in pharmaceutical compositions and composite particles and compositions thereof |
Jun, 2021
(2 years ago) | |
| US7736670 | NOVARTIS | Method of making particles for use in a pharmaceutical composition |
Jun, 2021
(2 years ago) | |
| US8479730 | NOVARTIS | Inhaler device |
Oct, 2028
(4 years from now) | |
| US8182838 | NOVARTIS | Dry powder composition comprising co-jet milled particles for pulmonary inhalation |
Oct, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 29, 2018 |
Drugs and Companies using GLYCOPYRROLATE ingredient
Market Authorisation Date: 29 October, 2015
Treatment: Long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd)
Dosage: POWDER;INHALATION
SEEBRI family patents
38. Starlix patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5463116 | NOVARTIS | Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them |
Oct, 2012
(11 years ago) | |
| US5488150 | NOVARTIS | Crystals of N-(trans-4-isopropylcyclohexycarbonyl)-D-phenylalanine and methods for preparing them |
Jan, 2013
(11 years ago) | |
| US6641841 | NOVARTIS | Tablet composition |
Nov, 2017
(6 years ago) | |
| US6844008 | NOVARTIS | Tablet composition |
Nov, 2017
(6 years ago) | |
| US6559188 | NOVARTIS | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes |
Sep, 2020
(3 years ago) | |
| US6878749 | NOVARTIS | Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes |
Sep, 2020
(3 years ago) | |
Drugs and Companies using NATEGLINIDE ingredient
Market Authorisation Date: 22 December, 2000
Treatment: Use as a blood glucose-lowering agent; Use for treatment of diabetes, particularly type 2 diabetes
Dosage: TABLET;ORAL
STARLIX family patents
39. Tafinlar patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7994185 | NOVARTIS | Benzene sulfonamide thiazole and oxazole compounds |
Jan, 2030
(5 years from now) | |
| US8415345 | NOVARTIS | Benzene sulfonamide thiazole and oxazole compounds |
Jan, 2030
(5 years from now) | |
| US8703781 | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors |
Oct, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8835443 | NOVARTIS | Pyrimidine compound and medical use thereof |
Jun, 2025
(1 year, 1 month from now) | |
|
US8835443 (Pediatric) | NOVARTIS | Pyrimidine compound and medical use thereof |
Dec, 2025
(1 year, 7 months from now) | |
| US9233956 | NOVARTIS | Benzene sulfonamide thiazole and oxazole compounds |
May, 2029
(5 years from now) | |
|
US9233956 (Pediatric) | NOVARTIS | Benzene sulfonamide thiazole and oxazole compounds |
Nov, 2029
(5 years from now) | |
|
US7994185 (Pediatric) | NOVARTIS | Benzene sulfonamide thiazole and oxazole compounds |
Jul, 2030
(6 years from now) | |
|
US8415345 (Pediatric) | NOVARTIS | Benzene sulfonamide thiazole and oxazole compounds |
Jul, 2030
(6 years from now) | |
| US8952018 | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors |
Oct, 2030
(6 years from now) | |
|
US8952018 (Pediatric) | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors |
Apr, 2031
(6 years from now) | |
|
US8703781 (Pediatric) | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors |
Apr, 2031
(6 years from now) | |
| US10869869 | NOVARTIS | Method of adjuvant cancer treatment |
Aug, 2033
(9 years from now) | |
|
US10869869 (Pediatric) | NOVARTIS | Method of adjuvant cancer treatment |
Mar, 2034
(9 years from now) | |
| US11504333 | NOVARTIS | Pharmaceutical composition |
Jun, 2038
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-182) | Apr 30, 2025 |
| Orphan Drug Exclusivity(ODE-183) | May 04, 2025 |
| Orphan Drug Exclusivity(ODE-147) | Jun 22, 2024 |
| Orphan Drug Exclusivity(ODE-428) | Mar 16, 2030 |
| New Indication(I-908) | Mar 16, 2026 |
| New Indication(I-894) | Jun 22, 2025 |
| Pediatric Exclusivity(PED) | Dec 22, 2025 |
| New Indication(I-745) | Jun 22, 2020 |
| New Indication(I-678) | Jan 08, 2017 |
| M(M-170) | Nov 20, 2018 |
| M(M-246) | Oct 06, 2022 |
| Orphan Drug Exclusivity(ODE-47) | May 29, 2020 |
| Orphan Drug Exclusivity(ODE-58) | Jan 09, 2021 |
| New Indication(I-778) | Apr 30, 2021 |
| New Indication(I-781) | May 04, 2021 |
| Orphan Drug Exclusivity(ODE) | May 29, 2020 |
| New Chemical Entity Exclusivity(NCE) | May 29, 2018 |
Drugs and Companies using DABRAFENIB MESYLATE ingredient
NCE-1 date: 22 December, 2024
Market Authorisation Date: 29 May, 2013
Treatment: Tafinlar is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations, as detected by an fda-approved test, and involvement of ...
Dosage: CAPSULE;ORAL; TABLET, FOR SUSPENSION;ORAL
TAFINLAR family patents
40. Tasigna patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7169791 | NOVARTIS | Inhibitors of tyrosine kinases |
Jul, 2023
(9 months ago) | |
| US8415363 | NOVARTIS | Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
Jul, 2026
(2 years from now) | |
| US8163904 | NOVARTIS | Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide |
Aug, 2028
(4 years from now) | |
| US9061029 | NOVARTIS | Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity |
Apr, 2032
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7169791 (Pediatric) | NOVARTIS | Inhibitors of tyrosine kinases |
Jan, 2024
(3 months ago) | |
| US8389537 | NOVARTIS | Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
Jul, 2026
(2 years from now) | |
| US8501760 | NOVARTIS | Pharmaceutical compositions comprising nilotinib or its salt |
Jul, 2026
(2 years from now) | |
|
US8389537 (Pediatric) | NOVARTIS | Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
Jan, 2027
(2 years from now) | |
|
US8415363 (Pediatric) | NOVARTIS | Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
Jan, 2027
(2 years from now) | |
|
US8501760 (Pediatric) | NOVARTIS | Pharmaceutical compositions comprising nilotinib or its salt |
Jan, 2027
(2 years from now) | |
| US8293756 | NOVARTIS | Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate |
Sep, 2027
(3 years from now) | |
|
US8293756 (Pediatric) | NOVARTIS | Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate |
Mar, 2028
(3 years from now) | |
|
US8163904 (Pediatric) | NOVARTIS | Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide |
Feb, 2029
(4 years from now) | |
|
US9061029 (Pediatric) | NOVARTIS | Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity |
Oct, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Mar 23, 2029 |
| Orphan Drug Exclusivity(ODE-171) | Mar 22, 2025 |
| Orphan Drug Exclusivity(ODE-172) | Mar 22, 2025 |
| Orphan Drug Exclusivity(ODE-380) | Sep 23, 2028 |
| New Dosing Schedule(D-170) | Dec 22, 2020 |
| New Patient Population(NPP) | Mar 22, 2021 |
| New Chemical Entity Exclusivity(NCE) | Oct 29, 2012 |
| New Indication(I-627) | Jun 17, 2014 |
| Orphan Drug Exclusivity(ODE) | Oct 29, 2014 |
Drugs and Companies using NILOTINIB HYDROCHLORIDE ingredient
NCE-1 date: 23 March, 2028
Market Authorisation Date: 22 March, 2018
Treatment: Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml); A method for the treatment of leukemias; Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml...
Dosage: CAPSULE;ORAL
TASIGNA family patents
41. Tekamlo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5559111 | NOVARTIS | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides |
Jul, 2018
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8613949 | NOVARTIS | Galenical formulations of organic compounds |
Dec, 2029
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 05, 2012 |
| New Combination(NC) | Aug 26, 2013 |
Drugs and Companies using ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE ingredient
NCE-1 date: 06 March, 2011
Market Authorisation Date: 26 August, 2010
Treatment: Treatment of hypertension
Dosage: TABLET;ORAL
TEKAMLO family patents
42. Trileptal patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7037525 | NOVARTIS | Oxacarbazepine film-coated tablets |
Feb, 2018
(6 years ago) | |
|
US7037525 (Pediatric) | NOVARTIS | Oxacarbazepine film-coated tablets |
Aug, 2018
(5 years ago) | |
| US8119148 | NOVARTIS | Suspension comprising oxcarbazepine |
Dec, 2020
(3 years ago) | |
|
US8119148 (Pediatric) | NOVARTIS | Suspension comprising oxcarbazepine |
Jun, 2021
(2 years ago) | |
Drugs and Companies using OXCARBAZEPINE ingredient
Market Authorisation Date: 14 January, 2000
Treatment: Method of treating seizures
Dosage: TABLET;ORAL; SUSPENSION;ORAL
TRILEPTAL family patents
43. Tykerb patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6391874 | NOVARTIS | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
Jul, 2017
(6 years ago) | |
| US6727256 | NOVARTIS | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
Jan, 2019
(5 years ago) | |
| US8513262 | NOVARTIS | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
Jan, 2019
(5 years ago) | |
| US6713485 | NOVARTIS | Heterocyclic compounds |
Sep, 2020
(3 years ago) | |
| US7157466 | NOVARTIS | Quinazoline ditosylate salt compounds |
Nov, 2021
(2 years ago) | |
| US8821927 | NOVARTIS | Pharmaceutical composition |
Sep, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6828320 | NOVARTIS | Heterocyclic compounds |
Jul, 2017
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-235) | Dec 06, 2021 |
| New Chemical Entity Exclusivity(NCE) | Mar 13, 2012 |
| New Indication(I-620) | Jan 29, 2013 |
Drugs and Companies using LAPATINIB DITOSYLATE ingredient
NCE-1 date: 14 March, 2011
Market Authorisation Date: 13 March, 2007
Treatment: Treatment of patients with breast cancer whose tumors overexpress the her2 receptor; Treatment of patients with advanced or metastatic breast cancer whose tumors overexpress her2 and who have received...
Dosage: TABLET;ORAL
TYKERB family patents
44. Tyzeka patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7858594 | NOVARTIS | Crystalline and amorphous forms of beta-L-2′-deoxythymidine |
Sep, 2023
(7 months ago) | |
| US7589079 | NOVARTIS | Crystalline and amorphous forms of beta-L-2′-deoxythymidine |
Sep, 2023
(7 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6444652 | NOVARTIS | β-L-2'-deoxy-nucleosides for the treatment of hepatitis B |
Aug, 2019
(4 years ago) | |
| US6395716 | NOVARTIS | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B |
Aug, 2019
(4 years ago) | |
| US7795238 | NOVARTIS | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B |
Aug, 2019
(4 years ago) | |
| US6566344 | NOVARTIS | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B |
Aug, 2019
(4 years ago) | |
| US6569837 | NOVARTIS | β-L-2′-deoxy pyrimidine nucleosides for the treatment of hepatitis B |
Oct, 2020
(3 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 25, 2011 |
| M(M-124) | Jan 28, 2016 |
Drugs and Companies using TELBIVUDINE ingredient
NCE-1 date: 25 October, 2010
Market Authorisation Date: 28 April, 2009
Treatment: Treatment of chronic hepatitis b in adult patients with evidence of viral replication and either evidence of persistent elevations in serum aminotransferases (alt or ast) or histologically active dise...
Dosage: SOLUTION;ORAL; TABLET;ORAL
TYZEKA family patents
45. Utibron patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6878721 | NOVARTIS | Beta2-adrenoceptor agonists |
Feb, 2025
(9 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6521260 | NOVARTIS | Carrier particles for use in dry powder inhalers |
Jan, 2016
(8 years ago) | |
| US6582678 | NOVARTIS | Carrier particles for use in dry powder inhalers |
Apr, 2018
(6 years ago) | |
| US7820694 | NOVARTIS | Beta-2-adrenoreceptor agonists |
Jun, 2020
(3 years ago) | |
| US8283362 | NOVARTIS | Beta-2-adrenoreceptor agonists |
Jun, 2020
(3 years ago) | |
| US8067437 | NOVARTIS | Beta-2-adrenoreceptor agonists |
Jun, 2020
(3 years ago) | |
| US8658673 | NOVARTIS | BETA2-adrenoreceptor agonists |
Jun, 2020
(3 years ago) | |
| US8796307 | NOVARTIS | Beta2-adrenoreceptor agonists |
Jun, 2020
(3 years ago) | |
| US8029768 | NOVARTIS | Treatment of respiratory diseases |
Apr, 2021
(3 years ago) | |
| US7229607 | NOVARTIS | Treatment of respiratory disease |
Apr, 2021
(3 years ago) | |
| US9931304 | NOVARTIS | Method of making particles for use in a pharmaceutical composition |
Jun, 2021
(2 years ago) | |
| US7736670 | NOVARTIS | Method of making particles for use in a pharmaceutical composition |
Jun, 2021
(2 years ago) | |
| US8048451 | NOVARTIS | Pharmaceutical compositions for inhalation |
Jun, 2021
(2 years ago) | |
| US8956661 | NOVARTIS | Method of making composite particles for use in pharmaceutical compositions and composite particles and compositions thereof |
Jun, 2021
(2 years ago) | |
| US8303991 | NOVARTIS | Method of making particles for use in a pharmaceutical composition |
Jun, 2021
(2 years ago) | |
| US8435567 | NOVARTIS | Pharmaceutical compositions of hydrophobic surface-modified active substance microparticles for inhalation |
Jun, 2021
(2 years ago) | |
| US9962338 | NOVARTIS | Method of making particles for use in a pharmaceutical composition |
Jun, 2021
(2 years ago) | |
| US8580306 | NOVARTIS | Particles for use in a pharmaceutical composition |
Jun, 2021
(2 years ago) | |
| US8479730 | NOVARTIS | Inhaler device |
Oct, 2028
(4 years from now) | |
| US8182838 | NOVARTIS | Dry powder composition comprising co-jet milled particles for pulmonary inhalation |
Oct, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 01, 2016 |
| New Product(NP) | Oct 29, 2018 |
Drugs and Companies using GLYCOPYRROLATE; INDACATEROL MALEATE ingredient
NCE-1 date: 02 July, 2015
Market Authorisation Date: 29 October, 2015
Treatment: Long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd)
Dosage: POWDER;INHALATION
UTIBRON family patents
46. Valturna patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5559111 | NOVARTIS | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides |
Jul, 2018
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8168616 | NOVARTIS | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
Jul, 2026
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 05, 2012 |
| New Combination(NC) | Sep 16, 2012 |
Drugs and Companies using ALISKIREN HEMIFUMARATE; VALSARTAN ingredient
NCE-1 date: 06 March, 2011
Market Authorisation Date: 16 September, 2009
Treatment: Treatment of hypertension
Dosage: TABLET;ORAL
VALTURNA family patents
47. Vigamox patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5607942 | NOVARTIS | 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives |
Mar, 2014
(10 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5607942 (Pediatric) | NOVARTIS | 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives |
Sep, 2014
(9 years ago) | |
| US6716830 | NOVARTIS | Ophthalmic antibiotic compositions containing moxifloxacin |
Sep, 2019
(4 years ago) | |
| US7671070 | NOVARTIS | Method of treating ophthalmic infections with moxifloxacin compositions |
Sep, 2019
(4 years ago) | |
|
US7671070 (Pediatric) | NOVARTIS | Method of treating ophthalmic infections with moxifloxacin compositions |
Mar, 2020
(4 years ago) | |
|
US6716830 (Pediatric) | NOVARTIS | Ophthalmic antibiotic compositions containing moxifloxacin |
Mar, 2020
(4 years ago) | |
Drugs and Companies using MOXIFLOXACIN HYDROCHLORIDE ingredient
Market Authorisation Date: 15 April, 2003
Treatment: Method of combating bacteria in a patient
Dosage: SOLUTION/DROPS;OPHTHALMIC
VIGAMOX family patents
48. Vijoice patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8476268 | NOVARTIS | Pyrrolidine-1,2-dicarboxamide derivatives |
Sep, 2029
(5 years from now) | |
| US8227462 | NOVARTIS | Pyrrolidine-1,2-dicarboxamide derivatives |
Apr, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 24, 2024 |
| Orphan Drug Exclusivity(ODE-396) | Apr 05, 2029 |
Drugs and Companies using ALPELISIB ingredient
NCE-1 date: 25 May, 2023
Market Authorisation Date: 05 April, 2022
Treatment: NA
Dosage: TABLET;ORAL
VIJOICE family patents
49. Vitravene Preservative Free patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5442049 | NOVARTIS | Oligonucleotides for modulating the effects of cytomegalovirus infections |
Aug, 2012
(11 years ago) | |
| US5595978 | NOVARTIS | Composition and method for treatment of CMV retinites |
Aug, 2012
(11 years ago) | |
Drugs and Companies using FOMIVIRSEN SODIUM ingredient
Market Authorisation Date: 26 August, 1998
Treatment: Treatment of cmv retinitis by intravitreal admin of a phosphorothioate oligonucleotide capable of hybridizing with cmv mrna
Dosage: INJECTABLE;INJECTION
VITRAVENE PRESERVATIVE FREE family patents
50. Votrient patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7262203 | NOVARTIS | Pyrimidineamines as angiogenesis modulators |
Dec, 2021
(2 years ago) | |
| US8114885 | NOVARTIS | Chemical compounds |
Dec, 2021
(2 years ago) | |
| US7105530 | NOVARTIS | Pyrimidineamines as angiogenesis modulators |
Oct, 2023
(6 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-23) | Apr 26, 2019 |
| New Chemical Entity Exclusivity(NCE) | Oct 19, 2014 |
| New Indication(I-649) | Apr 26, 2015 |
| Orphan Drug Exclusivity(ODE) | Apr 26, 2019 |
Drugs and Companies using PAZOPANIB HYDROCHLORIDE ingredient
NCE-1 date: 19 October, 2013
Market Authorisation Date: 19 October, 2009
Treatment: NA
Dosage: TABLET;ORAL
VOTRIENT family patents
51. Xiidra patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7745460 | NOVARTIS | Modulators of cellular adhesion |
Nov, 2024
(6 months from now) | |
| US7928122 | NOVARTIS | Modulators of cellular adhesion |
Nov, 2024
(6 months from now) | |
| US7314938 | NOVARTIS | Modulators of cellular adhesion |
Mar, 2025
(10 months from now) | |
| US8084047 | NOVARTIS | Compositions and methods for treatment of eye disorders |
May, 2026
(2 years from now) | |
| US9890141 | NOVARTIS | Crystalline pharmaceutical and methods of preparation and use thereof |
Oct, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9216174 | NOVARTIS | Modulators of cellular adhesion |
Nov, 2024
(6 months from now) | |
| US10124000 | NOVARTIS | Modulators of cellular adhesion |
Nov, 2024
(6 months from now) | |
| US7790743 | NOVARTIS | Modulators of cellular adhesion |
Nov, 2024
(6 months from now) | |
| US8592450 | NOVARTIS | Compositions and methods for treatment of eye disorders |
May, 2026
(2 years from now) | |
| US9447077 | NOVARTIS | Crystalline pharmaceutical and methods of preparation and use thereof |
Apr, 2029
(4 years from now) | |
| US8367701 | NOVARTIS | Crystalline pharmaceutical and methods of preparation and use thereof |
Apr, 2029
(4 years from now) | |
| US8168655 | NOVARTIS | Compositions and methods for treatment of eye disorders |
May, 2029
(5 years from now) | |
| US9353088 | NOVARTIS | Crystalline pharmaceutical and methods of preparation and use thereof |
Oct, 2030
(6 years from now) | |
| US8927574 | NOVARTIS | Crystalline pharmaceutical and methods of preparation and use thereof |
Nov, 2030
(6 years from now) | |
| US9085553 | NOVARTIS | LFA-1 inhibitor and methods of preparation and polymorph thereof |
Jul, 2033
(9 years from now) | |
| US11058677 | NOVARTIS | LFA-1 inhibitor formulations |
Dec, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 11, 2021 |
Drugs and Companies using LIFITEGRAST ingredient
NCE-1 date: 11 July, 2020
Market Authorisation Date: 11 July, 2016
Treatment: Treatment of the signs and symptoms of dry eye disease (ded); Treatment of signs and symptoms of dry eye disease (ded)
Dosage: SOLUTION/DROPS;OPHTHALMIC
XIIDRA family patents
52. Zometa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US4939130 | NOVARTIS | Substituted alkanediphosphonic acids and pharmaceutical use |
Sep, 2012
(11 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US4939130 (Pediatric) | NOVARTIS | Substituted alkanediphosphonic acids and pharmaceutical use |
Mar, 2013
(11 years ago) | |
| US8324189 | NOVARTIS | Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases |
May, 2025
(1 year, 1 month from now) | |
|
US8324189 (Pediatric) | NOVARTIS | Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases |
Nov, 2025
(1 year, 7 months from now) | |
| US7932241 | NOVARTIS | Pharmaceutical products comprising bisphosphonates |
Feb, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Sep 20, 2011 |
Drugs and Companies using ZOLEDRONIC ACID ingredient
Market Authorisation Date: 20 August, 2001
Treatment: Hypercalcemia of malignancy
Dosage: INJECTABLE;INTRAVENOUS
ZOMETA family patents
53. Zortress patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5665772 | NOVARTIS | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
Sep, 2019
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6440990 | NOVARTIS | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
Sep, 2013
(10 years ago) | |
|
US6440990 (Pediatric) | NOVARTIS | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
Mar, 2014
(10 years ago) | |
| US6004973 | NOVARTIS | Pharmaceutical compositions comprising rafamycin coprecipitates |
Jul, 2016
(7 years ago) | |
|
US6004973 (Pediatric) | NOVARTIS | Pharmaceutical compositions comprising rafamycin coprecipitates |
Jan, 2017
(7 years ago) | |
| US6239124 | NOVARTIS | Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin |
Jul, 2017
(6 years ago) | |
| US6455518 | NOVARTIS | Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin |
Jul, 2017
(6 years ago) | |
|
US6455518 (Pediatric) | NOVARTIS | Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin |
Jan, 2018
(6 years ago) | |
|
US6239124 (Pediatric) | NOVARTIS | Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin |
Jan, 2018
(6 years ago) | |
|
US5665772 (Pediatric) | NOVARTIS | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
Mar, 2020
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 20, 2013 |
| New Chemical Entity Exclusivity(NCE) | Mar 30, 2014 |
| New Indication(I-668) | Feb 15, 2016 |
| Pediatric Exclusivity(PED) | Oct 20, 2013 |
Drugs and Companies using EVEROLIMUS ingredient
NCE-1 date: 30 September, 2013
Market Authorisation Date: 20 April, 2010
Treatment: Prophylaxis of organ rejection in adult patients at low-moderate immunologic risk receiving a renal transplant
Dosage: TABLET;ORAL
ZORTRESS family patents
54. Zykadia patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7153964 | NOVARTIS | Pyrimidine compounds |
Feb, 2021
(3 years ago) | |
| US9416112 | NOVARTIS | 2,4-pyrimidinediamine compounds and their uses |
Jan, 2023
(1 year, 2 months ago) | |
| US8835430 | NOVARTIS | 2,4-pyrimidinediamine compounds and their uses |
Jan, 2023
(1 year, 2 months ago) | |
| US8188276 | NOVARTIS | 2,4-pyrimidinediamine compounds and their uses |
Jan, 2023
(1 year, 2 months ago) | |
| US9018204 | NOVARTIS | 2,4-pyrimidinediamine compounds and their uses |
Jan, 2023
(1 year, 2 months ago) | |
| US7893074 | NOVARTIS | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
Apr, 2026
(1 year, 11 months from now) | |
| US8399450 | NOVARTIS | Compounds and compositions as protein kinase inhibitors |
Nov, 2027
(3 years from now) | |
| US7964592 | NOVARTIS | 2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
Apr, 2028
(4 years from now) | |
| US8039479 | NOVARTIS | Compounds and compositions as protein kinase inhibitors |
Jun, 2030
(6 years from now) | |
| US8039474 | NOVARTIS | 2,3,4,9-tetrahydro-1H-carbazole derivatives as CRTH2 receptor antagonists |
Jun, 2030
(6 years from now) | |
| US9309229 | NOVARTIS | Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine |
Jan, 2032
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8377921 | NOVARTIS | Compounds and compositions as protein kinase inhibitors |
Nov, 2027
(3 years from now) | |
| US8703787 | NOVARTIS | Methods of using ALK inhibitors |
Feb, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| ODE*(ODE*) | May 26, 2024 |
| New Chemical Entity Exclusivity(NCE) | Apr 29, 2019 |
Drugs and Companies using CERITINIB ingredient
NCE-1 date: 29 April, 2018
Market Authorisation Date: 18 March, 2019
Treatment: Treatment of a cancer mediated by an anaplastic lymphoma kinase (alk)
Dosage: CAPSULE;ORAL
ZYKADIA family patents